Market Considerations in Europe Outlook - Featured Research on Jazz Pharmaceuticals, Inc. and Dendreon Corporation
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 11/15/11 -- Today, introduced featured coverage of Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) and Dendreon Corporation (NASDAQ: DNDN). Full research reports are available to readers at: .
With the European Financial Stability Facility set to increase to $1.4 trillion, it marks a significant move forward to strengthen the safety net in place for Europe's most troubled countries. Private bondholders of Greek debt are settling at a 50% haircut as another $180 billion in fresh aid is set to arrive, enabling banks to recapitalize at a healthy 9% reserve. Overall, these measures will bring Greece's debt burden down to 120% of GDP by 2020. An important consideration is political commitment to this road map. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.
Bollinger Report screened and selected Jazz Pharmaceuticals, Inc. for its current position within the healthcare industry. Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the identification, development and commercialization of pharmaceutical products. A copy of this report featuring Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) is available at: .
Bollinger Report is featuring Dendreon Corporation for its changing role within the healthcare industry. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. To download researches and analysis on Dendreon Corporation (NASDAQ: DNDN) we welcome investors to visit: .
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
Contact:
Martin Schwartz
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.11.2011 - 14:00 Uhr
Sprache: Deutsch
News-ID 88004
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Market Considerations in Europe Outlook - Featured Research on Jazz Pharmaceuticals, Inc. and Dendreon Corporation"
steht unter der journalistisch-redaktionellen Verantwortung von
Bollinger Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
